D46.3 Refractory anemia with excess blasts in transformation

Name of the Condition

• Refractory anemia with excess blasts in transformation

Summary

Refractory anemia with excess blasts in transformation is a type of myelodysplastic syndrome (MDS) characterized by low blood cell counts and a high proportion of immature cells (blasts) in the bone marrow. The condition is termed "refractory" because it does not respond to standard treatments for anemia. It represents a high-risk subtype of MDS due to its potential to progress rapidly to acute myeloid leukemia (AML).

Causes

The exact cause of refractory anemia with excess blasts in transformation is often unknown. It may involve genetic mutations that disrupt normal blood cell production. Other factors can include previous chemotherapy or radiation therapy, exposure to certain chemicals (e.g., benzene), and rarely, inherited bone marrow failure syndromes.

Risk Factors

• Age (most common in individuals over 60)
• Previous cancer treatment with chemotherapy or radiation
• Exposure to industrial chemicals like benzene
• Family history of MDS or other blood disorders
• Certain genetic conditions (e.g., Fanconi anemia)

Symptoms

• Fatigue or weakness
• Frequent infections
• Easy or unexplained bruising or bleeding
• Shortness of breath
• Pale skin
• Unexplained weight loss

Diagnosis

Diagnosis involves a complete blood count (CBC) to identify cytopenias, followed by a bone marrow biopsy to assess cell dysplasia and blast count. Cytogenetic analysis may be performed to detect chromosomal abnormalities, and additional tests may evaluate for progression to acute leukemia.

Treatment Options

Treatment focuses on managing symptoms and reducing the risk of progression. Options may include blood transfusions, growth factors, chemotherapy, or stem cell transplantation. The choice of therapy depends on the patient’s age, overall health, and blast count.

Prognosis and Follow-Up

Prognosis is poor due to the high risk of progression to acute myeloid leukemia. Regular monitoring of blood counts and bone marrow status is essential. Follow-up care may involve frequent blood tests and periodic bone marrow evaluations to assess disease progression.

Complications

• Rapid progression to acute myeloid leukemia
• Severe anemia requiring transfusions
• Increased risk of infections
• Bleeding complications due to low platelet counts

Lifestyle & Prevention

• Avoid exposure to chemicals like benzene
• Maintain a balanced diet to support overall health
• Practice good hygiene to reduce infection risk
• Follow up regularly with a hematologist

When to Seek Professional Help

Seek immediate medical attention if you experience severe fatigue, unexplained bleeding, high fever, or signs of infection. These may indicate disease progression or complications requiring urgent care.

Tips for Medical Coders

Document the blast count and any evidence of transformation to acute leukemia. Ensure the diagnosis aligns with the criteria for refractory anemia with excess blasts in transformation, including bone marrow findings and clinical presentation. Code D46.3 is specific to this high-risk MDS subtype and should not be used for other MDS variants.